May 02, 2013
Gilead Reports Interim Data From Phase 2 LONESTAR Study
-- Company Plans to Initiate Phase 3 Study Evaluating Eight and 12 Weeks of Therapy with Sofosbuvir and Ledipasvir for the Treatment of Chronic Hepatitis C --
The design of ION-3 was based on interim results from the Phase 2 LONESTAR study, which evaluated eight- and 12-week courses of therapy with the once-daily fixed-dose combination of sofosbuvir and ledipasvir with and without RBV in 60 treatment-naïve, non-cirrhotic patients.
In this study, 19/19 patients in the 12-week arm had a sustained virologic response four weeks after completing therapy (SVR4) and 40/41 in the eight-week arms had a sustained virologic response eight weeks after stopping therapy (SVR8), with one relapse occurring in the arm receiving sofosbuvir/ledipasvir without RBV.
Two additional cohorts in the LONESTAR study evaluated a 12-week course of the fixed-dose combination of sofosbuvir and ledipasvir with or without RBV in 40 patients who had previously failed therapy with an HCV-specific protease inhibitor-based regimen. Half of these treatment-experienced patients have documented, compensated cirrhosis. Ninety-five percent of patients in both arms achieved SVR4, one cirrhotic patient in the sofosbuvir and ledipasvir arm relapsed and one patient in the sofosbuvir and ledipasvir plus RBV arm was lost to follow-up.
Interim results from LONESTAR are summarized in the table below. Further details from this study will be presented at a future scientific meeting.
|Sofosbuvir + ledipasvir||8 weeks||GT 1 treatment-naïve||95% (19/20) SVR 8|
|Sofosbuvir + ledipasvir + RBV||8 weeks||GT 1 treatment-naïve||100% (21/21) SVR 8|
|Sofosbuvir + ledipasvir||12 weeks||GT 1 treatment-naïve||100% (19/19) SVR 4|
|Sofosbuvir + ledipasvir||12 weeks||GT 1 treatment-experienced||95% (18/19) SVR 4|
|Sofosbuvir + ledipasvir + RBV||12 weeks||GT 1 treatment-experienced||95% (20/21) SVR 4|
“The LONESTAR results suggest that once-daily all-oral therapy with the
nucleotide NS5B inhibitor sofosbuvir and the NS5A inhibitor ledipasvir
may have the potential to cure most genotype 1 HCV infected patients
with a remarkably short treatment duration,” said
Both sofosbuvir in combination with ledipasvir, and sofosbuvir in combination with ledipasvir and RBV were well tolerated in the LONESTAR study.
“Based upon the encouraging data derived from LONESTAR, we are
continuing to advance our research evaluating new drug combinations and
shorter durations of all-oral therapy that have the potential to
simplify treatment for those living with hepatitis C,” commented
ION-3 is a randomized, open label Phase 3 clinical trial evaluating the efficacy and safety of sofosbuvir and ledipasvir for the treatment of chronic HCV in non-cirrhotic, treatment-naïve genotype 1 infected patients. Participants will be randomized to receive sofosbuvir and ledipasvir for eight weeks (n=200), sofosbuvir and ledipasvir plus RBV for eight weeks (n=200), or sofosbuvir and ledipasvir for 12 weeks (n=200). The primary endpoint of the study is SVR12, defined as maintaining undetectable HCV RNA 12 weeks post-treatment and considered a cure for HCV infection. The study is designed to assess non-inferiority of the eight-week treatment duration arms to the 12-week treatment duration arm.
Two other ongoing Phase 3 studies are examining all-oral HCV therapy with sofosbuvir and ledipasvir. ION-1 and ION-2 are testing 12- and 24-week courses of the fixed-dose combination with and without RBV among treatment-naïve and treatment-experienced genotype 1 HCV patients, including those with compensated cirrhosis. Based on the results of the LONESTAR trial, Gilead has amended ION-2 to shorten the duration of therapy in one of the two fixed-dose combination arms without RBV from 24 to 12 weeks.
Additional information about ION-1, ION-2, ION-3 and LONESTAR can be found at www.clinicaltrials.gov.
Sofosbuvir, ledipasvir and the fixed-dose combination tablet are investigational products and their safety and efficacy have not yet been established.
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the
possibility of unfavorable results from the clinical studies evaluating
sofosbuvir and the sofosbuvir and ledipasvir fixed-dose combination,
including from the ION-1, ION-2 and ION-3 and LONESTAR studies. Gilead
also faces risks related to its ability to enroll patients in the ION-3
study, the need to modify or delay the study and the risk of failing to
obtain approval of sofosbuvir and/or the sofosbuvir and ledipasvir
fixed-dose combination from regulatory authorities. As a result,
sofosbuvir and the sofosbuvir and ledipasvir fixed-dose combination may
never be successfully commercialized. In addition, Gilead may make a
strategic decision to discontinue development of these products if, for
example, Gilead believes commercialization will be difficult relative to
other opportunities in its pipeline. These risks, uncertainties and
other factors could cause actual results to differ materially from those
referred to in the forward-looking statements. The reader is cautioned
not to rely on these forward-looking statements. These and other risks
are described in detail in Gilead’s Annual Report on Form 10-K for the
For more information on
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)